Pharvaris jumps as oral therapy for genetic disorder meets main goal in late-stage trial

Pharvaris NV

03/12/2025 13:33

** Shares of oral therapy developer Pharvaris PHVS.O rise 11.9% to $27 premarket

** Co's oral therapy, Deucrictibant, for on-demand treatment of hereditary angioedema (HAE) attacks meets primary endpoint

** HAE attacks are sudden episodes of severe swelling in different parts of the body caused by a genetic disorder

 ** PHVS says the treatment demonstrated faster treatment response and symptom relief compared to placebo

** Co says it remains on track to submit the new drug application with the U.S. FDA in the first half of 2026

** PHVS up 25.8% YTD, up to last close

(Reporting by Utkarsh Tushar Hathi in Bengaluru)

((utkarshtushar.hathi@thomsonreuters.com))